Suppr超能文献

复方口服避孕药使用者发生静脉血栓形成的风险预测

Risk prediction of developing venous thrombosis in combined oral contraceptive users.

作者信息

McDaid Aaron, Logette Emmanuelle, Buchillier Valérie, Muriset Maude, Suchon Pierre, Pache Thierry Daniel, Tanackovic Goranka, Kutalik Zoltán, Michaud Joëlle

机构信息

Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland.

Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.

出版信息

PLoS One. 2017 Jul 27;12(7):e0182041. doi: 10.1371/journal.pone.0182041. eCollection 2017.

Abstract

BACKGROUND

Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified.

METHODS AND FINDINGS

Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69-0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged.

CONCLUSION

We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use.

摘要

背景

静脉血栓栓塞症(VTE)是一种受遗传和环境风险因素影响的复杂多因素疾病。后者的一个例子是经常使用复方口服避孕药(CC),这会使发生VTE的风险增加3至7倍,具体取决于雌激素剂量和药丸中所含孕激素的类型。每1000名使用CC的女性中就有1人会发生血栓形成,且往往会带来终身后果;因此在进行此类治疗之前有必要进行风险评估。目前已知的与VTE发生相关的临床风险因素通常由医生常规检查,然而即使与凝血因子V莱顿突变和凝血因子II G20210A变异的基因检测相结合,它们也远远不足以进行风险预测。因此,应确定与使用CC相关的血栓形成发展所特有的临床尤其是遗传风险因素。

方法与结果

对1622名使用CC的女性群体应用逐步(逻辑)模型选择,其中一半(794名)在使用避孕药期间发生了血栓栓塞事件。在模型选择中测试了46种多态性和临床参数,并确定了4种临床风险因素和9种多态性的特定组合。在这9种多态性中,有两种新的基因多态性(rs1799853和rs4379368),以前未与血栓栓塞事件的发生相关联。在交叉验证环境中,这个新的预测模型优于先前发表的针对一般血栓栓塞事件的模型(AUC 0.71,95% CI 0.69 - 0.74)。应考虑在独立人群中进行进一步验证。

结论

我们确定了两个与VTE发展相关的新基因变异,以及一个强大的预测模型,用于评估使用复方口服避孕药的女性发生血栓形成的风险。该模型优于当前的医疗实践以及先前发表的模型,是第一个针对使用CC的特定模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d64c/5531518/ea5c7857d343/pone.0182041.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验